Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676524 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL310184 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL122230 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL259733 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL9496224 | 0.79 | TSHR (0.64) | HPGDLMNAMEN1KMT2A | |
| SCHEMBL30995990 | 0.79 | SRC (0.64) | SRCL3MBTL1TDP1KDM4E | |
| Water SCHEMBL7889250 | 0.78 | SRC (0.56) | SRCL3MBTL1TDP1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL29186320 | 0.78 | SRC (0.56) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL5019770 | 0.78 | SRC (0.56) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL19212985 | 0.78 | SRC (0.56) | SRCL3MBTL1TDP1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11712715-B2 | Surface modification in the vapor phase | Quantum-Si Incorporated (US) | 2023-08-01 | — | — | US | disclosed |
| US-11707519-B2 | Phosphorylated heptose compounds: process for their preparation and use | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND (IE) | 2023-07-25 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210139783-A1 | FLAME RETARDANT LEVULINIC ACID-BASED COMPOUNDS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2021-05-13 | — | — | US | disclosed |
| US-20190106630-A1 | FLAME RETARDANT LEVULINIC ACID-BASED COMPOUNDS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-0549073-B1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI SA (FR) | 1997-03-26 | — | — | EP | disclosed |
| US-5296496-A | Treating degenerative diseases | STERLING WINTHROP INC. (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-4301280-A | Preparation of 3-substituted cephalosporins | LILLY INDUSTRIES LIMITED (GB) | 1981-11-17 | — | — | US | disclosed |
| EP-0019401-A1 | Process for preparing enamine derivatives, compounds so produced and process for preparing a 3-hydroxy-cephalosporin | Lilly Industries Limited (GB) | 1980-11-26 | — | — | EP | disclosed |
| US-4188382-A | Thiazolinyl (thiazolyl) phosphonamidates and phosphoramidates pesticidal and herbicidal compositions based thereon | Vsesojuzny Nauchno, et al. (SU) | 1980-02-12 | — | — | US | disclosed |
| US-4113680-A | Method for preparing 17 α-ester-21-halo pregnanes | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707519-B2 | Phosphorylated heptose compounds: process for their preparation and use | PPP6C, G6PD, PFKFB1 | SRC 472/4885L3MBTL1 4401/4885TDP1 3328/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | SRC 709/4885L3MBTL1 2681/4885TDP1 78/4885 |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | SRC 3202/4885L3MBTL1 1538/4885TDP1 39/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | SRC 2380/4885L3MBTL1 2435/4885TDP1 1262/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SRC 3397/4885L3MBTL1 3066/4885TDP1 2792/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | SRC 3385/4885L3MBTL1 837/4885TDP1 607/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | SRC 4806/4885L3MBTL1 1863/4885TDP1 92/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | SRC 3085/4885L3MBTL1 3935/4885TDP1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.